Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-743 in Metastatic Osteosarcoma
NCT00005625Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 1999
- Primary completion
- Sep 2003
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in osteosarcoma (OS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate. Started Dec 1999; status: completed.
02
Drugs
trabectedin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT00005625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005625.